ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck

Joseph K. Salama, Nabil Saba, Harry Quon, Madhur K. Garg, Joshua Lawson, Mark W. McDonald, John A. Ridge, Richard V. Smith, Anamaria Reyna Yeung, Sue S. Yom, Jonathan J. Beitler

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3-4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies. Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread. Post-operative radiotherapy concurrent with cisplatin at 100 mg/m2 every 21 days is the current standard chemoradiotherapy platform adjuvant head and neck cancer treatment. Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and neck subsites and nodal regions. Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients.

Original languageEnglish (US)
Pages (from-to)554-559
Number of pages6
JournalOral Oncology
Volume47
Issue number7
DOIs
StatePublished - Jul 2011

Fingerprint

Chemoradiotherapy
Radiotherapy
Head and Neck Neoplasms
Neoplasms
Neck
Therapeutics
Adjuvant Chemoradiotherapy
Radiation
Recurrence
Adjuvant Radiotherapy
Survival
Cisplatin
Disease-Free Survival
Carcinoma, squamous cell of head and neck
Lymph Nodes
Head
Margins of Excision

Keywords

  • Adjuvant head and neck
  • Appropriateness criteria
  • Chemoradiotherapy
  • Head and neck cancer
  • Post-operative chemoradiotherapy head and neck
  • Post-operative radiotherapy head and neck

ASJC Scopus subject areas

  • Oncology
  • Oral Surgery
  • Cancer Research

Cite this

ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. / Salama, Joseph K.; Saba, Nabil; Quon, Harry; Garg, Madhur K.; Lawson, Joshua; McDonald, Mark W.; Ridge, John A.; Smith, Richard V.; Yeung, Anamaria Reyna; Yom, Sue S.; Beitler, Jonathan J.

In: Oral Oncology, Vol. 47, No. 7, 07.2011, p. 554-559.

Research output: Contribution to journalArticle

Salama, JK, Saba, N, Quon, H, Garg, MK, Lawson, J, McDonald, MW, Ridge, JA, Smith, RV, Yeung, AR, Yom, SS & Beitler, JJ 2011, 'ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck', Oral Oncology, vol. 47, no. 7, pp. 554-559. https://doi.org/10.1016/j.oraloncology.2011.05.002
Salama, Joseph K. ; Saba, Nabil ; Quon, Harry ; Garg, Madhur K. ; Lawson, Joshua ; McDonald, Mark W. ; Ridge, John A. ; Smith, Richard V. ; Yeung, Anamaria Reyna ; Yom, Sue S. ; Beitler, Jonathan J. / ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. In: Oral Oncology. 2011 ; Vol. 47, No. 7. pp. 554-559.
@article{a8ea19ab86a64c3691e0c541ae33366d,
title = "ACR appropriateness criteria{\circledR} adjuvant therapy for resected squamous cell carcinoma of the head and neck",
abstract = "Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3-4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies. Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread. Post-operative radiotherapy concurrent with cisplatin at 100 mg/m2 every 21 days is the current standard chemoradiotherapy platform adjuvant head and neck cancer treatment. Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and neck subsites and nodal regions. Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients.",
keywords = "Adjuvant head and neck, Appropriateness criteria, Chemoradiotherapy, Head and neck cancer, Post-operative chemoradiotherapy head and neck, Post-operative radiotherapy head and neck",
author = "Salama, {Joseph K.} and Nabil Saba and Harry Quon and Garg, {Madhur K.} and Joshua Lawson and McDonald, {Mark W.} and Ridge, {John A.} and Smith, {Richard V.} and Yeung, {Anamaria Reyna} and Yom, {Sue S.} and Beitler, {Jonathan J.}",
year = "2011",
month = "7",
doi = "10.1016/j.oraloncology.2011.05.002",
language = "English (US)",
volume = "47",
pages = "554--559",
journal = "Oral Oncology",
issn = "1368-8375",
publisher = "Elsevier Limited",
number = "7",

}

TY - JOUR

T1 - ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck

AU - Salama, Joseph K.

AU - Saba, Nabil

AU - Quon, Harry

AU - Garg, Madhur K.

AU - Lawson, Joshua

AU - McDonald, Mark W.

AU - Ridge, John A.

AU - Smith, Richard V.

AU - Yeung, Anamaria Reyna

AU - Yom, Sue S.

AU - Beitler, Jonathan J.

PY - 2011/7

Y1 - 2011/7

N2 - Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3-4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies. Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread. Post-operative radiotherapy concurrent with cisplatin at 100 mg/m2 every 21 days is the current standard chemoradiotherapy platform adjuvant head and neck cancer treatment. Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and neck subsites and nodal regions. Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients.

AB - Locoregional recurrence following surgical resection alone for stage III/IV head and neck cancer is common. Adjuvant radiotherapy has been shown to improve post-operative locoregional control when compared to pre-operative radiotherapy for head and neck cancers. Following surgical resection, adverse pathological features determine the need for adjuvant therapy. High-risk pathologic features include extranodal tumor spread and involved surgical margins. Other adverse pathologic features include T 3-4 tumors, perineural invasion, lymphovascular space invasion, low neck adenopathy, and multiple tumor involved cervical lymph nodes. The standard adjuvant therapies are post-operative radiation therapy or post-operative chemoradiotherapy. Post-operative chemoradiotherapy yields superior locoregional control, progression-free survival, and in some studies, overall survival compared to post-operative radiotherapy for high-risk patients in multiple randomized studies. Pooled analyses of randomized data demonstrate that post-operative concurrent chemoradiotherapy is associated with overall survival benefits for patients with involved surgical margins as well as those with extranodal tumor spread. Post-operative radiotherapy concurrent with cisplatin at 100 mg/m2 every 21 days is the current standard chemoradiotherapy platform adjuvant head and neck cancer treatment. Post-operative radiotherapy and post-operative chemoradiotherapy radiation treatment volumes are not standardized and should be designed based on the risk of recurrence and clinically occult involvement of head and neck subsites and nodal regions. Evidence supports a post-operative radiotherapy and chemoradiotherapy radiation dose of at least 63 Gy for high-risk patients and at least 57 Gy for low risk patients.

KW - Adjuvant head and neck

KW - Appropriateness criteria

KW - Chemoradiotherapy

KW - Head and neck cancer

KW - Post-operative chemoradiotherapy head and neck

KW - Post-operative radiotherapy head and neck

UR - http://www.scopus.com/inward/record.url?scp=79959726830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959726830&partnerID=8YFLogxK

U2 - 10.1016/j.oraloncology.2011.05.002

DO - 10.1016/j.oraloncology.2011.05.002

M3 - Article

C2 - 21664857

AN - SCOPUS:79959726830

VL - 47

SP - 554

EP - 559

JO - Oral Oncology

JF - Oral Oncology

SN - 1368-8375

IS - 7

ER -